Literature DB >> 1468582

Soluble interferon-alpha receptor molecules are present in body fluids.

D Novick1, B Cohen, M Rubinstein.   

Abstract

Soluble forms of the interferon-alpha receptor (sIFN-alpha R) were identified in human serum and urine by Western blotting with monoclonal antibodies (MAb) directed against IFN-alpha R, and by immunoprecipitation (Iptn) of a covalently cross-linked complex of IFN-alpha R and [125I]IFN-alpha with anti IFN-alpha MAb. Elevated levels of sIFN-alpha R were found in sera of hairy cell leukemia patients. The soluble receptor from serum migrated as a 55 kDa protein in SDS-PAGE, and, as expected, the cross-linked product migrated as a 75 kDa protein. The soluble receptor from urine was found to be a protein of mol. wt. 45 kDa and its cross-linked complex migrated as a 65 kDa protein. The calculated mol. wt. of the entire extracellular domain of the IFN-alpha R prior to post-translational modifications is 47,000. Since there are 12 potential glycosylation points in this extracellular domain, its actual mol. wt. may be as high as 70,000 Da. It is therefore concluded that sIFN-alpha R molecules, corresponding to truncated forms of the extracellular domain of the cell surface IFN-alpha R, are present in human serum and in normal human urine.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1468582     DOI: 10.1016/0014-5793(92)81523-o

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  11 in total

Review 1.  Antitumour actions of interferons: implications for cancer therapy.

Authors:  Belinda S Parker; Jai Rautela; Paul J Hertzog
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

2.  Impaired HCV clearance in HIV/HCV coinfected subjects treated with PegIFN and RBV due to interference of IFN signaling by IFNαR2a.

Authors:  Yu-Jin Lee; Xiaozhen Zhang; Estefania Vazquez; Gayathri Shivasabesan; Howard A Young; Alison Murphy; Honghui Wang; Anthony F Suffredini; Ulrich Siebenlist; Shyam Kottilil
Journal:  J Interferon Cytokine Res       Date:  2013-10-30       Impact factor: 2.607

3.  A panel of synthetic antibodies that selectively recognize and antagonize members of the interferon alpha family.

Authors:  S Miersch; S Kuruganti; M R Walter; S S Sidhu
Journal:  Protein Eng Des Sel       Date:  2017-09-01       Impact factor: 1.650

Review 4.  Soluble receptors for cytokines and growth factors: generation and biological function.

Authors:  S Rose-John; P C Heinrich
Journal:  Biochem J       Date:  1994-06-01       Impact factor: 3.857

5.  Ligand-induced association of the type I interferon receptor components.

Authors:  B Cohen; D Novick; S Barak; M Rubinstein
Journal:  Mol Cell Biol       Date:  1995-08       Impact factor: 4.272

6.  Viral etiology of Parkinson's disease: Focus on influenza A virus.

Authors:  T Yamada
Journal:  Parkinsonism Relat Disord       Date:  1996-07       Impact factor: 4.891

7.  Decreased Type I Interferon Production by Plasmacytoid Dendritic Cells Contributes to Severe Dengue.

Authors:  Vinit Upasani; Carolina Scagnolari; Federica Frasca; Nikaïa Smith; Vincent Bondet; Axelle Vanderlinden; Sokchea Lay; Heidi Auerswald; Sothy Heng; Denis Laurent; Sowath Ly; Veasna Duong; Guido Antonelli; Philippe Dussart; Darragh Duffy; Tineke Cantaert
Journal:  Front Immunol       Date:  2020-12-17       Impact factor: 7.561

8.  Differential tyrosine phosphorylation of the IFNAR chain of the type I interferon receptor and of an associated surface protein in response to IFN-alpha and IFN-beta.

Authors:  C Abramovich; L M Shulman; E Ratovitski; S Harroch; M Tovey; P Eid; M Revel
Journal:  EMBO J       Date:  1994-12-15       Impact factor: 11.598

9.  Interleukin-6 and interleukin-6 receptor secretion by chronic lymphatic leukaemia and normal B lymphocytes: effect of PMA and PWM.

Authors:  I Drucker; A Klajman; M Revel; Y Manor; S Ben-Efraim; D Novick
Journal:  Mediators Inflamm       Date:  1997       Impact factor: 4.711

10.  Antiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-ß Mediation.

Authors:  Isaac Hurtado-Guerrero; Bruno Hernáez; María J Pinto-Medel; Esther Calonge; José L Rodriguez-Bada; Patricia Urbaneja; Ana Alonso; Natalia Mena-Vázquez; Pablo Aliaga; Shohreh Issazadeh-Navikas; José Pavia; Laura Leyva; José Alcamí; Antonio Alcamí; Óscar Fernández; Begoña Oliver-Martos
Journal:  J Clin Med       Date:  2020-03-31       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.